Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 106, Issue 1, 2007, Pages 221-232

  Secord, Angeles Alvarez ^a   Darcy, Kathleen M ^b   Hutson, Alan ^b   Lee, Paula S ^a   Havrilesky, Laura J ^a   Grace, Lisa A ^a   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; bFGF; Ovarian carcinoma; p53; THBS 1; VEGF

Indexed keywords

ANGIOGENIC PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; PROTEIN P53; THROMBOSPONDIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HAZARD RATIO; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

AGED; ANGIOGENIC PROTEINS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34250304711     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.03.021     Document Type: Article

References (74)

1. Diaz-Flores L., Gutierrez R., and Varela H. Angiogenesis: an update. Histol. Histopathol. 9 (1994) 807-843
2. Ferrara N., and Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5 (1999) 1359-1364
3. Burke P.A., and DeNardo S.J. Antiangiogenic agents and their promising potential in combined therapy. Crit. Rev. Oncol. Hematol. 39 (2001) 155-171
4. Ferrara N., CarverMoore K., Chen H., Dowd M., Lu L., Oshea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
5. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
6. Sonmezer M., Gungor M., Ensari A., and Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int. J. Gynecol. Cancer 14 (2004) 82-88
7. Nakanishi Y., Kodama J., Yoshinouchi M., Tokumo K., Kamimura S., Okuda H., et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 16 (1997) 256-262
8. Paley P.J., Staskus K.A., Gebhard K., Mohanraj D., Twiggs L.B., Carson L.F., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80 (1997) 98-106
9. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 76 (1997) 1221-1227
10. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., and Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90 (1998) 447-454
11. Obermair A., Speiser P., Reisenberger K., Ullrich R., Czerwenka K., Kaider A., et al. Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett. 130 (1998) 69-76
12. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
13. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., Groshen S., et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. 89 (1997) 219-227
14. Tuszynski G.P., Gasic T.B., Rothman V.L., Knudsen K.A., and Gasic G.J. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res. 47 (1987) 4130-4133
15. Wong S.Y., Purdie A.T., and Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am. J. Pathol. 140 (1992) 1473-1482
16. Wang T.N., Qian X., Granick M.S., Solomon M.P., Rothman V.L., Berger D.H., et al. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J. Surg. Res. 63 (1996) 39-43
17. Taraboletti G., Morbidelli L., Donnini S., Parenti A., Granger H.J., Giavazzi R., et al. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 14 (2000) 1674-1676
18. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., and Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54 (1994) 6504-6511
19. Zabrenetzky V., Harris C.C., Steeg P.S., and Roberts D.D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59 (1994) 191-195
20. Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., Lawler J., and Roberts D.D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100 (1999) 1423-1431
21. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
22. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 106-115
23. Havrilesky L., Darcy K.M., Hamdan H., Priore R.L., Leon J., Bell J., et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3814-3825
24. Havrilesky L.J., Alvarez A.A., Whitaker R.S., Marks J.R., and Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol. Oncol. 83 (2001) 491-500
25. 2 from contingency tables, and the calculation of P. J. R. Stat. Soc. 85 (1922) 87-94
26. Mehta C.R., and Patel N.R. A network algorithm for performing Fisher's exact test in r × c contingency tables. J. Am. Stat. Assoc. 78 (1983) 427-434
27. Hosmer D.W., and Lemeshow S. Applied logistic regression (2000), Chichester, Wiley, New York
28. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53 (1958) 457-481
29. Savage I.R. Contributions to the theory of rank order statistics-The two sample case. Ann. Math. Stat. 27 (1956) 590-615
30. Cox D.R. Regression models and life tables. J. R. Stat. Soc. 34 (1972) 187-220
31. George D.J., Halabi S., Shepard T.F., Sanford B., Vogelzang N.J., Small E.J., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B9480. Clin. Cancer Res. 11 (2005) 1815-1820
32. Kodama J., Hashimoto I., Seki N., Hongo A., Yoshinouchi M., Okuda H., et al. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res. 21 (2001) 2983-2987
33. Oshia G., Kijima H., Himeno S., Kenmochi T., Kise Y., Tanaka H., et al. Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res. 19 (1999) 4375-4378
34. Straume O., and Akslen L.A. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am. J. Pathol. 59 1 (2001) 223-235
35. Trotter M.J., Colwell R., and Tron V.A. Thrombospondin-1 and cutaneous melanoma. J. Cutan. Med. Surg. 7 (2003) 136-141
36. Aishima S., Taguchi K., Sugimachi K., Asayama Y., Nishi H., Shimada M., et al. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma. Int. J. Surg. Pathol. 10 1 (2002) 47-57
37. Tobita K., Kijima H., Dowaki S., Oida Y., Kashiwagi I., Ishii M., et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int. J. Oncol. 21 6 (2002) 1189-1195
38. Poon R.T., Chung K.K., Cheung S.T., Lau C.P., Tong S.W., Leung K.L., et al. Clinical significance of thrombospondin-1 expression in hepatocellular carcinoma. Clin. Cancer Res. 10 12 Pt 1 (2004) 4150-4157
39. Sutton C.D., O'Byrne K., Goddard J.C., Marshall L.J., Jones L., Garcea G., et al. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin. Cancer Res. 11 18 (2005) 6567-6573
40. Tringler B., Grimm C., Sliutz G., Leodolter S., Speiser P., Reinthaller A., et al. Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma. Gynecol. Oncol. 99 (2005) 80-83
41. Iachim E., Michael M.C., Salmas M., Damala K., Tsanou E., Michael M.M., et al. BMC Cancer 6 (2006) 140
42. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., Groshen S., et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. 89 3 (1997) 219-227
43. Yao L., Zhao Y.L.., Itoh S., Wada S., Yue L., and Furuta I. Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival. Oral Oncol 36 6 (2000) 539-544
44. Kodama J., Hashimoto I., Seki N., Hongo A., Yoshinouchi M., Okuda H., et al. Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis. Clin. Cancer Res. 7 9 (2001) 2826-2831
45. Maeda K., Nishiguchi Y., Yashiro M., Yamada S., Onoda N., Sawada T., et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int. J. Mol. Med. 5 4 (2000) 373-378
46. Maeda K., Nishiguchi Y., Kang S.M., Yashiro M., Onoda N., Sawada T., et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol. Rep. 8 4 (2001) 763-766
47. Miyanaga K., Kato Y., Makamura T., Matsumura M., Amaya H., Horiuchi T., et al. Expression and role of thromobospon-1 in colorectal cancer. Anticancer Res. 22 6C (2002) 3941-3948
48. Kaio E., Tanaka S., Oka S., Hiyama T., Kitadai Y., Haruma K., et al. Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int. J. Oncol. 23 4 (2003) 901-911
49. Yamaguchi M., Sugio K., Ondo K., Yano T., and Sugimachi K. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36 (2002) 143-150
50. Alvarez A.A., Axelrod J.R., Whitaker R.S., Isner P.D., Bentley R.C., Dodge R.K., et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol. Oncol. 82 (2001) 273-278
51. Karavasilis V., Malamou-Mitsi V., Briasoulis E., Tsanou E., Kitsou E., and Pavlidis N. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int. J. Gynecol. Cancer 16 (2004) 241-246
52. Salvesen H.B., and Akslen L.A. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer 84 5 (1999) 538-543
53. Seki N., Kodama J., Hashimoto I., Hongo A., Yoshinouchi M., and Kudo T. Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis. Int. J. Cancer 19 2 (2001) 305-310
54. Ohta Y., Shridhar V., Kalemkerin G.P., Bright R.K., Watanabe Y., and Pass H.I. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 85 12 (1999) 2570-2576
55. Gasparini G., Toi M., Biganzoli E., Dittadi R., Fanelli M., Morabito A., et al. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology 60 1 (2001) 72-80
56. Linderholm B., Karlsson E., Klaar S., Lindahl T., Borg A.L., Elmberger G., et al. Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers. Eur. J. Cancer 40 16 (2004) 2417-2423
57. Dudek A.Z., and Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Investig. 23 3 (2005) 193-200
58. Tang D., Nagano H., Yamamoto H., Wada H., Nakamura M., Kondo M., et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol. Rep. 15 3 (2006) 525-532
59. Varani J., Dixit V.M., Fligiel S.E., McKeever P.E., and Carey T.E. Thrombospondin-induced attachment and spreading of human squamous carcinoma cells. Exp. Cell Res. 167 (1986) 376-390
60. Albo D., Arnoletti J.P., Castiglioni A., Granick M.S., Solomon M.P., Rothman V.L., et al. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem. Biophys. Res. Commun. 203 (1994) 857-865
61. Arnoletti J.P., Albo D., Granick M.S., Solomon M.P., Castiglioni A., Rothman V.L., et al. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76 (1995) 998-1005
62. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130 (1995) 503-506
63. Gao A.G., Lindberg F.P., Dimitry J.M., Brown E.J., and Frazier W.A. Thrombospondin modulates alpha v beta 3 function through integrin-associated protein. J. Cell Biol. 135 (1996) 533-544
64. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138 (1997) 707-717
65. Mukhopadhyay D., and Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. 14 (2005) 123-130
66. Goodheart M.J., Vasef M.A., Sood A.K., Davis C.S., and Buller R.E. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol. Oncol. 86 (2002) 85-90
67. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B., et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol. Oncol. 92 (2004) 927-935
68. Pal S., Datta K., and Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61 (2001) 6952-6957
69. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q.W., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha. Genes Dev. 14 (2000) 34-44
70. Joo Y.E., Sohn Y.H., Lee W.S., Park C.H., Choi S.K., Rew J.S., et al. Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas. Korean J. Intern. Med. 17 (2002) 153-159
71. Joo Y.E., Sohn Y.H., Joo S.Y., Lee W.S., Min S.W., Park C.H., et al. The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J. Intern. Med. 17 (2002) 211-219
72. Horiuchi A., Imai T., Shimizu M., Oka K., Wang C., Nikaido T., et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res. 22 (2002) 2697-2702
73. Shahin M.S., Hughes J.H., Sood A.K., and Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89 (2000) 2006-2017
74. Harada H., Nakagawa K., Iwata S., Saito M., Kumon Y., Sakaki S., et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 59 (1999) 3783-3789